Amphastar Pharmaceuticals, Inc. has grown revenue 11% a year over three years and 14% a year over five, with earnings per share compounding at −4.5%. Revenue growth, 3-year annual rate: +11% (Drug Manufacturers - Specialty & Generic median +13%). Revenue growth, 5-year rate: +14%, growth has slowed since the five-year average. Earnings per share, 3-year rate: −4.5%, earnings lagged revenue: the growth is costing something. Years of annual history on file: 14, FY2012 to FY2025, as filed.

AMPHAmphastar Pharmaceuticals, Inc.

Healthcare

$25.83+0.00% 1Y

$25.83

$16.8752 weeks$29.40

Is it growing?

Watch

Growth is fading: earnings down −37% year on year and operating margin narrowing (−9.5 points).

2 to watch, 1 neutral

Revenue trend+1% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +14% a year.

Earnings trend−37% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction−9.5 points operating

Trailing-twelve-month operating margin, 15.6% now against 25.0% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is AMPH growing?

Amphastar Pharmaceuticals, Inc. has grown revenue 11% a year over three years and 14% a year over five, with earnings per share compounding at −4.5%.

+11%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +13% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +14%
Revenue growth, 5-year rate · +11% over three · growth has slowed since the five-year average
Earnings per share, 3-year rate: −4.5%
Earnings per share, 3-year rate · revenue +11% · earnings lagged revenue: the growth is costing something
Years of annual history on file: 14
Years of annual history on file · FY2012 to FY2025, as filed